Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient

Vedolizumab is a humanized monoclonal integrin blocker with gut selective effects on lymphocyte trafficking. Its efficacy and safety for the treatment of moderate to severe Crohn’s disease and ulcerative colitis were demonstrated by phase III GEMINI studies (GEMINI 1 trial: Vedolizumab as Induction...

Descripción completa

Detalles Bibliográficos
Autores principales: Groudan, Kevin, Gupta, Kamesh, Singhania, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797417/
https://www.ncbi.nlm.nih.gov/pubmed/33457145
http://dx.doi.org/10.7759/cureus.12582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797417/
https://www.ncbi.nlm.nih.gov/pubmed/33457145
http://dx.doi.org/10.7759/cureus.12582

Ejemplares similares